2015 Quick Reference Chart for the WHO Medical Eligibility Criteria for Contraceptive Use –

to initiate or continue use of combined oral contraceptives (COCs), depot-medroxyprogesterone acetate (DMPA), progestin-only implants, copper intrauterine device (Cu-IUD)

CONDITION	Sub-condition	cc	oc_	DN	1PA	lmp	lants	Cu-l	UD
Pregnancy		N	A	N	Α	N	Α		
Breastfeeding	Less than 6 weeks postpartum							See i.	
	6 weeks to < 6 months postpartum								i. ا
	6 months postpartum or more								
Postpartum and not breastfeeding	< 21days								
	< 21days with other risk factors for VTE*							ر ا	.
VTE = venous throm- boembolism	≥ 21 to 42 days with other risk factors for VTE*							See i.	<u> </u>
	> 42 days								
Postpartum and breastfeeding or not breastfeeding	< 48 hours or more than 4 weeks			See ii.					
	≥ 48 hours to less than 4 weeks	See ii.			See ii.				
	Puerperal sepsis								
Postabortion	Immediate post-septic								
Smoking	Age ≥ 35 years, < 15 cigarettes/day								
	Age ≥ 35 years, ≥ 15 cigarettes/day								
Multiple risk factors for cardiovascular disease									
Hypertension	History of (where BP cannot be evaluated)								
BP = blood pressure	BP is controlled and can be evaluated								
, , , , , , , , , , , , , , , , , , ,	Elevated BP (systolic 140 - 159 or diastolic 90 - 99)								
	Elevated BP (systolic ≥ 160 or diastolic ≥ 100)								
	Vascular disease								
Deep venous thrombosis (DVT) and pulmonary	History of DVT/PE								
	Acute DVT/PE								
	DVT/PE, established on anticoagulant therapy								
embolism (PE)	Major surgery with prolonged immobilization								
Known thrombogenic mutations									
Ischemic heart disease (current or history of) or stroke (history of)						1	С		
Known hyperlipidemias									
Complicated valve	ular heart disease								
Systemic lupus erythematosus	Positive or unknown antiphospholipid antibodies								
	Severe thrombocytopenia			1	С			1	С
	Immunosuppressive treatment							I	C
Headaches	Non-migrainous (mild or severe)	Τ	С						
	Migraine without aura (age < 35 years)	1	С						
	Migraine without aura (age ≥ 35 years)	1	C						
	Migraines with aura (at any age)			_	С	1	С		

CONDITION	Sub-condition Sub-condition	coc	DMPA	Implants	Cu-IUD		
Unexplained vaginal bleeding (prior to evaluation)					-1	С	
Gestational trophoblastic	Regressing or undetectable β-hCG levels						
disease	Persistently elevated β-hCG levels or malignant disease						
Cancers	Cervical (awaiting treatment)				1	C	
	Endometrial				1	С	
	Ovarian				1	С	
Breast disease	Undiagnosed mass	**	**	**			
	Current cancer						
	Past w/ no evidence of current disease for 5 yrs						
Uterine distortion due to fibroids or anatomical abnormalities							
STIs/PID	Current purulent cervicitis, chlamydia, gonorrhea					С	
	Vaginitis						
	Current pelvic inflammatory disease (PID)				1	U	
	Other STIs (excluding HIV/hepatitis)						
	Increased risk of STIs						
	Very high individual risk of exposure to STIs				1	С	
Pelvic tuberculosis					-1	С	
Diabetes	Nephropathy/retinopathy/neuropathy						
	Diabetes for > 20 years						
Symptomatic gall bladder disease (current or medically treated)							
Cholestasis (history of)	Related to pregnancy						
	Related to oral contraceptives						
Hepatitis	Acute or flare	I C					
	Chronic or client is a carrier						
Cirrhosis	Mild						
	Severe						
Liver tumors (hepatocellular adenoma and malignant hepatoma)							
High risk of HIV o	r HIV-infected (Stage 1 or 2)						
AIDS (HIV-infected Stage 3 or 4)	No antiretroviral therapy (ARV)	See iii.	See iii.	See iii.	1	С	
	Improved to Stage 1 or 2 on ARV therapy						
	Not improved on ARV therapy				1	С	
Drug interactions	Rifampicin or rifabutin						
	Anticonvulsant therapy***						
This shart shaves a say	mplete list of all conditions classified by WHO as Category 3	and 1					

This chart shows a complete list of all conditions classified by WHO as Category 3 and 4.

Source: Adapted from Medical Eligibility Criteria for Contraceptive Use, 5th Edition. Geneva: World Health Organization, 2015.

Available: http://www.who.int/reproductivehealth/publications/family_planning/en/index.html

- Category 1 There are no restrictions for use.
- Category 2 Generally use; some follow-up may be needed.
- Category 3 Usually not recommended; clinical judgment and continuing access to clinical services are required for use.
- Category 4 The method should not be used.



- I/C Initiation/Continuation: A woman may fall into either one category or another, depending on whether she is initiating or continuing to use a method. Where I/C is not marked, the category is the same for initiation and continuation.
- NA Not Applicable: Women who are pregnant do not require contraception. If these methods are accidentally initiated, no harm will result.
- i See condition "Postpartum and breastfeeding or not breastfeeding" instead.
- ii See condition "Breastfeeding" or condition "Postpartum and not breastfeeding" instead.
- iii Women who use methods other than IUDs can use them regardless of HIV stage or use of ART.
- Other risk factors for VTE include: previous VTE, thrombophilia, immobility, transfusion at delivery, BMI > 30 kg/m2. postpartum hemorrhage, immediately post-caesarean delivery, pre-eclampsia, and smoking.
- Evaluation of an undiagnosed mass should be pursued as soon as possible.
- *** Anticonvulsants include: phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine, and lamotrigine. Lamotrigine is a category 1 for implants.

